Two-Drug combo shows promise against brain metastases in advanced melanoma
NCT ID NCT03873818
First seen Jan 10, 2026 · Last updated Apr 28, 2026 · Updated 25 times
Summary
This study tested a combination of two immunotherapy drugs (low-dose ipilimumab and pembrolizumab) in 24 people with advanced melanoma that had spread to the brain. The goal was to see if the treatment could shrink or control the brain tumors and to check for side effects. Participants received the drugs intravenously, and the study measured how many had their cancer stop growing for at least six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE BRAIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.